March 28th 2023
Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.
FDA Approves First Biosimilar for Cancer TreatmentSeptember 18th 2017
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
Some Older Women Still Need Cervical Cancer ScreeningMay 17th 2017
The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
SLN Biopsy Alone Can Reduce Surgical Morbidity in Early Cervical CancerMarch 13th 2017
The use of sentinel lymph node biopsy alone in women with early cervical cancer resulted in less surgical morbidity without a significant increase in the risk of recurrence, according to a new prospective study.
HIV Infection Decreases Survival in Women With Invasive Cervical CancerAugust 30th 2016
HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
Ernest Hawk Discusses the NCI-Designated Cancer Centers’ Joint Statement on the HPV VaccineJuly 15th 2016
In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.
Cisplatin/Paclitaxel Plus RT Offers Good Results in Advanced Cervical CancerJune 22nd 2016
A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
AXAL Immunotherapy Well-Tolerated in Recurrent Metastatic Cervical CancerJune 16th 2016
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
ASCO Releases Resource-Stratified Invasive Cervical Cancer GuidelinesMay 25th 2016
ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
Immunotherapy: New Strategies for the Treatment of Gynecologic MalignanciesJanuary 16th 2016
In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.
Uptick in HPV Vaccinations Highest in Hispanic, High Poverty CommunitiesJanuary 15th 2016
Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.
Questions We Should Be Asking About Bevacizumab for Cervical CancerMay 15th 2015
There is good evidence that angiogenesis plays a central role in cervical cancer pathogenesis, suggesting a strong rationale for adding anti-angiogenesis agents to chemotherapeutic agents for the treatment of this disease.